Table 3. Tumour characteristics according to the primary site.
| Tumour characteristic | Duodenum, n=32 (51%) | Jejunum, n=18 (29%) | Ileum, n=13 (20%) | P-value |
|---|---|---|---|---|
| Stages I–II (n=19) |
8 (42%) |
7 (37%) |
4 (21%) |
|
| Stage III (n=22) |
13 (59%) |
5 (23%) |
4 (18%) |
0.81 |
| Stage IV (n=20) |
9 (45%) |
6 (30%) |
5 (25%) |
|
| Poorly differentiated (n=13) |
5 (38%) |
3 (24%) |
5 (38%) |
0.23 |
| P53 overexpression (n=26) |
13 (50%) |
8 (31%) |
5 (19%) |
0.89 |
| Abnormal β-catenin (n=12) |
4 (33%) |
3 (25%) |
5 (42%) |
0.16 |
| dMMR phenotype (n=14) |
9 (64%) |
5 (36%) |
0 (0%) |
0.07 |
| Mutated KRAS (n=21) |
12 (57%) |
6 (29%) |
3 (14%) |
0.73 |
| HER2 expression 2+ (n=2) | 0 (0%) | 0 (0%) | 2 (100%) | — |
Abbreviation: dMMR=mismatch repair deficiency.